Global Liposomal Doxorubicin Market Report to 2032: Featuring Pfizer, Sun Pharmaceutical Industries, Cipla and Cadila Pharmaceuticals - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Nov 10, 2022--

The "Liposomal Doxorubicin Market" report has been added to ResearchAndMarkets.com's offering.

A recent market study published on Liposomal Doxorubicin offers a global industry analysis for 2015-2021 and opportunity assessment for 2022-2032.

The study offers a comprehensive assessment of the most important market dynamics.

After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

Companies Mentioned

• Pfizer Inc
• Sun Pharmaceutical Industries Ltd
• Cipla Inc
• Cadila Pharmaceuticals

Market Segmentation

The global Liposomal Doxorubicin Market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.

By Products

• J7J (Doxil/Caelyx)
• Sun Pharma (Lipodox)
• Teva (Myocet))

By Application

• Leukemia
• Bone Sarcoma
• Breast Cancer
• Endometrial Cancer
• Gastric Cancer
• Liver Cancer
• Kidney Cancer
• Multiple Myeloma
• Ovarian Cancer
• Kaposi Sarcoma

By Region

• North America
• Europe
• Asia Pacific
• Middle East and Africa (MEA)
• Latin America

For more information about this report visit https://www.researchandmarkets.com/r/ha5znt

View source version on businesswire.com:https://www.businesswire.com/news/home/20221110005689/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2022.